GB Sciences Inc Stock News

Gb Sciences (GBLX) was issued a new patent by the U.S. Patent and Trademark Office ((USPTO)) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present…

This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.

Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixture

Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Mond

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixt

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. LAS VEGAS,

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.  LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 / Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc.

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique